During recent years we have developed a DNA-based drug (a plasmid vector) constructed from the H19 regulatory sequence (H19 promoter) that is used to drive the expression of Diphtheria toxin A chain (DT-A) specifically to the cancer cells that express the H19 lncRNA. The gene discussed is H19; the disease is cancer.